CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $17,440,000 | -4.0% | 4,000,000 | 0.0% | 0.62% | -0.2% |
| Q1 2021 | $18,160,000 | -20.9% | 4,000,000 | 0.0% | 0.62% | -16.5% |
| Q4 2020 | $22,960,000 | -20.7% | 4,000,000 | 0.0% | 0.74% | -26.3% |
| Q3 2020 | $28,960,000 | +314.9% | 4,000,000 | +100.0% | 1.00% | +226.1% |
| Q2 2020 | $6,980,000 | +135.8% | 2,000,000 | 0.0% | 0.31% | +52.0% |
| Q1 2020 | $2,960,000 | -24.5% | 2,000,000 | 0.0% | 0.20% | -9.0% |
| Q4 2019 | $3,920,000 | -38.8% | 2,000,000 | +60.0% | 0.22% | -52.2% |
| Q3 2019 | $6,400,000 | -28.5% | 1,250,000 | 0.0% | 0.46% | -39.7% |
| Q2 2019 | $8,950,000 | -46.1% | 1,250,000 | 0.0% | 0.77% | -59.9% |
| Q1 2019 | $16,600,000 | +0.7% | 1,250,000 | -40.3% | 1.92% | -5.7% |
| Q4 2018 | $16,480,000 | -29.0% | 2,094,000 | 0.0% | 2.04% | -20.9% |
| Q3 2018 | $23,202,000 | -17.4% | 2,094,000 | 0.0% | 2.58% | -19.1% |
| Q2 2018 | $28,101,000 | -20.3% | 2,094,000 | -22.8% | 3.18% | -15.4% |
| Q1 2018 | $35,242,000 | +278.2% | 2,712,986 | +167.8% | 3.76% | +120.9% |
| Q4 2017 | $9,319,000 | +14.1% | 1,012,986 | 0.0% | 1.70% | -8.4% |
| Q3 2017 | $8,165,000 | +233.5% | 1,012,986 | +138.3% | 1.86% | +219.4% |
| Q2 2017 | $2,448,000 | -26.8% | 425,000 | -45.3% | 0.58% | -20.3% |
| Q1 2017 | $3,342,000 | – | 777,202 | – | 0.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |